Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLargo, Inc. (OTCQX: BLGO) SEC filings page on Stock Titan provides access to the company’s official reports and current disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports describing material events such as contract terminations, legal actions, investor presentations, and equity-related transactions, as well as other periodic and annual filings available through EDGAR.
For a cleantech and life sciences company like BioLargo, SEC filings offer detail on its technology portfolio, licensing and manufacturing agreements, and capital structure that may not appear in press releases alone. Recent 8-K filings, for example, describe the termination of a license and preferred master manufacturing agreement related to pet odor control products, potential impairment of a note receivable, and the filing of a federal lawsuit to protect patented CupriDyne odor control technology. Other 8-Ks discuss investor presentation materials for events such as LD Micro and NobleCon, and the conversion of unpaid salary and expenses by officers into locked-up common stock.
Through this page, users can review BioLargo’s disclosures about material agreements, legal proceedings, financial considerations tied to specific contracts, and corporate actions involving its common stock. Stock Titan enhances this access with AI-powered summaries that help explain the significance of complex filings, including key points from Form 8-K reports and other documents. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track how BioLargo reports on its environmental technologies, medical subsidiaries, licensing relationships, and governance matters over time.
BioLargo, Inc. director and President received additional common stock as compensation. On 12/31/2025, the reporting person acquired 130,222 shares of BioLargo common stock at $0.1843 per share, in exchange for a reduction of salary and unreimbursed business expenses. After this transaction, the reporting person beneficially owned 10,523,625 shares of BioLargo common stock, held directly, which includes shares held through a limited liability company that the reporting person owns and controls. The newly issued shares are subject to a lock-up agreement and cannot be sold until BioLargo reports at least $40 million in gross revenue for any reported period, or its market capitalization exceeds $300 million, or there is a change in control of the company.
BioLargo, Inc. director compensation included an equity component for the most recently completed quarterly period. On 12/31/2025, the reporting person received an option to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share. This option was issued in lieu of $18,750 in board fees owed, under BioLargo’s 2024 Equity Incentive Plan.
Following this grant, the reporting person beneficially owned 1,265,761 derivative securities, reported as held directly. The filing indicates the person’s role as a director and that the report is filed for a single reporting person.
BioLargo, Inc. reported that one of its directors received a new stock option grant as part of board compensation. On 12/31/2025, the director was granted an option to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share. The option becomes exercisable on 12/31/2025 and expires on 12/31/2035, giving the director a 10-year window to exercise once vested. After this grant, the director beneficially owned 1,265,761 derivative securities tied to the company’s stock. The filing explains that the option was issued in lieu of $18,750 in fees owed for serving on the board for the most recently completed quarter, under BioLargo’s 2024 Equity Incentive Plan, highlighting the company’s use of equity-based compensation for its directors.
BioLargo, Inc. director reported receiving a stock option grant as compensation for board service. On 12/31/2025, the director was issued an option to purchase 81,389 shares of common stock at an exercise price of $0.1843 per share. This award was given in lieu of $15,000 in fees owed for the most recently completed quarterly period and was granted under the company’s 2024 Equity Incentive Plan. Following this grant, the director beneficially owned 2,359,510 derivative securities, all held directly.
BioLargo, Inc. director reports new stock option grants for board service. A company director filed a Form 4 disclosing two stock option awards dated 12/31/2025. One option to purchase 122,084 shares of common stock at an exercise price of $0.1843 per share was granted to replace an earlier option for 45,000 shares that had compensated $22,500 of services and had recently expired unexercised. A second option to purchase 101,736 shares at $0.17 per share was issued as payment of $18,750 in fees for service on the board for the most recently completed quarter under BioLargo’s 2024 Equity Incentive Plan. Both options are exercisable on 12/31/2025 and expire on 12/31/2035, reflecting equity-based compensation to the director instead of cash.
BioLargo, Inc. reported that on November 14, 2025 two company officers agreed to convert an aggregate $99,901 of unpaid salary and unreimbursed business expenses into common stock. The shares were issued at a price of $0.16 per share, resulting in an aggregate issuance of 624,383 shares of BioLargo common stock. These shares are subject to a Lock-Up Agreement dated as of the issuance date, meaning they cannot be sold until BioLargo reports at least $40 million in consolidated gross revenue for any reported period, or its market capitalization exceeds $300 million, or the company undergoes a change in control.
BioLargo, Inc. (BLGO) reported an insider stock acquisition by a director and Chief Science Officer on a Form 4. On 11/14/2025, the reporting person acquired 313,754 shares of common stock at $0.16 per share through an exchange for accrued salary and unreimbursed business expenses. After this transaction, the insider beneficially owns 25,751,505 common shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
The newly issued shares are subject to a lock-up agreement. They cannot be sold until BioLargo reports at least $40 million in gross revenue for any consolidated reporting period, or its market capitalization exceeds $300 million, or there is a change in control of the company.
BioLargo, Inc. (BLGO) reported that a director and officer who is also its President acquired 310,269 shares of common stock on 11/14/2025 at $0.16 per share. The shares were issued by the company in exchange for a reduction of amounts owed to the insider for salary and unreimbursed business expenses.
The newly issued shares are subject to a lock-up agreement and cannot be sold until BioLargo reports at least $40 million in consolidated gross revenue for any period, or its market capitalization exceeds $300 million, or there is a change in control. Following this transaction, the reporting person beneficially owns 10,393,403 shares in total, including 1,528,695 shares held indirectly through a limited liability company.
BioLargo (BLGO) reported a sharply weaker Q3 2025 as a major customer default triggered a large credit loss. Revenue was $1.103 million versus $4.351 million a year ago, with gross profit of $372,000. Operating expenses rose to $7.552 million, including a $3.849 million credit loss expense tied to impaired receivables and a note from a customer following contract and payment disputes now in litigation.
The quarter’s net loss was $7.244 million (vs. $1.060 million). Year to date, revenue was $7.148 million and net loss $11.047 million. Cash and equivalents were $4.546 million with current assets of $5.775 million and current liabilities of $3.451 million, yielding working capital of $2.324 million. The company stated that gross profits for 2025 will not fund operations and raised “substantial doubt” about its ability to continue as a going concern without additional revenue or financing.
Customer concentration remained high, with one customer representing 35% of Q3 revenue and 64% year to date. Cash from financing activities totaled $7.269 million for the first nine months, while operating cash used was $6.707 million. Shares outstanding were 313,762,657 as of November 12, 2025.
BioLargo, Inc. (BLGO) furnished an investor presentation under Item 7.01 (Regulation FD). The company plans to present the slide deck attached as Exhibit 99.1 during an investor webcast on November 14, 2025 at 1:30 PM Pacific Time.
The information is expressly stated as furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act nor incorporated by reference into other filings. The company notes Safe Harbor language applies to forward-looking statements in the slides. Exhibits include 99.1 (slide deck) and 104 (Cover Page Inline XBRL).